Lyon and New York, October 6, 2016 – The Medicrea Group (Alternext Paris: FR0004178572 -
ALMED), worldwide leader pioneering the development and manufacture of personalized analytical
services and implant solutions for the treatment of complex spinal conditions, announced its sales for the
3rd quarter ending September 30, 2016.
Sales reached a total of €6.8 million over the third quarter, down 3% compared to the same quarter of
2015, due to a temporary decrease in activity in Europe.
Year-to-date 2016, Medicrea sales have increased by 3% thanks to its priority markets, the United
States (+9%) and France (+13%) where the adoption of UNiD™patient-specific technology is continuing
with more than 100 surgeons utilizing this service and the significant 1,000 UNiD™ surgery milestone
anticipated within the next month.
Outlook:
Medicrea is currently participating in the Eurospine congress in Berlin from the 5th to the 7th of October
and will be present at the world’s largest convention for spine specialists organized by the NASS (North
American Spine Society) in Boston from the 26th to the 29th of October. During this event, the company
is expected to announce a major development related to the UNiD™ services and personalized
treatment modalities.
From early September, the Group has undertaken the relocation of production facilities and office
headquarters to its new site near Lyon, gathering all the activities in a single infrastructure to improve
productivity and optimize collaboration between the various support teams.
Next publication: 2016 annual sales published January 12, 2017, after market.
Medicrea specializes in the design, manufacture, and distribution of innovative proprietary technologies
devoted exclusively to spinal surgery. Operating in a $10 billion market, Medicrea operates with 150
employees, including 40 at its Medicrea USA Corp. subsidiary based in New York City.
Medicrea is the only company to offer personalized value-based healthcare solutions to the global
complex spine market. The Company has driven innovation in Spine by focusing development on
market-disrupting technologies focused on patient outcomes, including the growing UNiD™ Technology
Platform of Patient-Specific Implants and Analytical Services, which received the first-ever FDA
Clearance in November 2014 for a personalized spinal treatment modality.
Medicrea has uniquely positioned itself outside of the traditional implant manufacturer’s role in order to
engage with each market player as a collaborator, offering customized implants to patients,
personalized services to doctors and immediate cost-savings to providers. By leveraging its proprietary
software analysis tools with big data technologies, Medicrea is well-placed to improve the efficacy of
spinal care efficiency for all stakeholders in this market.
Contacts: Medicrea
Denys Sournac, Founder, CEO
dsournac@medicrea.com
Tel.: +33 (0)4 72 01 87 87
Fabrice Kilfiger, CFO fkilfiger@medicrea.com
Tel.: +33 (0)4 72 01 87 87
Published at MEDICREA (IM)PROVE
No comments:
Post a Comment